Xtl Biopharmaceuticals Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
4
- Stock Symbol
-
XTLB
- Investments
-
5
- Share Price
-
$0.02
- (As of Wednesday Closing)
Xtl Biopharmaceuticals General Information
Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Contact Information
Website
www.xtlbio.comCorporate Office
- 5 Badner Street
- Post Office Box Number 8241
- Ramat Gan 5218102
- Israel
Corporate Office
- 5 Badner Street
- Post Office Box Number 8241
- Ramat Gan 5218102
- Israel
Xtl Biopharmaceuticals Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $12.6M | 545M | 1.54M |
Xtl Biopharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 12,312 | 3,209 | 1,922 | 11,912 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,823) | (1,383) | 428 | |
| Net Income | (378) | (1,782) | (1,348) | 435 |
| Total Assets | 2,928 | 2,426 | 4,186 | 6,618 |
| Total Debt | 0 | 0 | 0 | 0 |
Xtl Biopharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Xtl Biopharmaceuticals Comparisons
Industry
Financing
Details
Xtl Biopharmaceuticals Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Vicore Pharma Holding | Formerly VC-backed | Stockholm, Sweden | ||||
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Ona Therapeutics | Venture Capital-Backed | Barcelona, Spain | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan |
Xtl Biopharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Xtl Biopharmaceuticals Patents
Xtl Biopharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200338195-A1 | Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus | Inactive | 11-Aug-2016 | ||
| US-20180043016-A1 | Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus | Inactive | 11-Aug-2016 | ||
| US-20180043017-A1 | Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosus | Inactive | 11-Aug-2016 | ||
| US-20090054477-A1 | 4-thio substituted quinoline and naphthyridine compounds | Active | 22-Aug-2007 | ||
| US-8143276-B2 | 4-thio substituted quinoline and naphthyridine compounds | Inactive | 22-Aug-2007 | C07D215/36 |
Xtl Biopharmaceuticals Executive Team (7)
| Name | Title | Board Seat |
|---|---|---|
| Shlomo Shalev | Chief Executive Officer & Board Member | |
| Itay Weinstein | Chief Financial Officer, Finance |
Xtl Biopharmaceuticals Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Doron Turgeman | Self | Chairman & Board Member | |
| Iris Yalon | Self | Board Member | |
| John Waymack MD | Purple Biotech | Board Member & President | |
| Osnat Fain | Self | Board Member | |
| Shlomo Shalev | Xtl Biopharmaceuticals | Chief Executive Officer & Board Member |
Xtl Biopharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Xtl Biopharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Xtl Biopharmaceuticals Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| The Social Proxy | 14-Aug-2024 | Database Software | |||
| Cannomed Medical Cannabis Industries | 21-Nov-2012 | Drug Discovery | |||
| Canndoc Pharma | 25-Jul-2012 | Pharmaceuticals | |||
| VivoQuest | 20-Sep-2005 | Biotechnology | |||
| IviGene | 12-Mar-2001 | Corporate | Biotechnology |
Xtl Biopharmaceuticals Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| The Social Proxy | Database Software | Tel Aviv, Israel | 2021 |
| Canndoc Pharma | Pharmaceuticals | Herzliya, Israel |
Xtl Biopharmaceuticals Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cannomed Medical Cannabis Industries | 21-Nov-2012 | Completed |
|
||
| IviGene | 12-Mar-2001 | Corporate | Completed |
Xtl Biopharmaceuticals FAQs
-
When was Xtl Biopharmaceuticals founded?
Xtl Biopharmaceuticals was founded in 1993.
-
Who is the CEO of Xtl Biopharmaceuticals?
Shlomo Shalev is the CEO of Xtl Biopharmaceuticals.
-
Where is Xtl Biopharmaceuticals headquartered?
Xtl Biopharmaceuticals is headquartered in Ramat Gan, Israel.
-
What is the size of Xtl Biopharmaceuticals?
Xtl Biopharmaceuticals has 4 total employees.
-
What industry is Xtl Biopharmaceuticals in?
Xtl Biopharmaceuticals’s primary industry is Drug Discovery.
-
Is Xtl Biopharmaceuticals a private or public company?
Xtl Biopharmaceuticals is a Public company.
-
What is Xtl Biopharmaceuticals’s stock symbol?
The ticker symbol for Xtl Biopharmaceuticals is XTLB.
-
What is the current stock price of Xtl Biopharmaceuticals?
As of 09-Oct-2024 the stock price of Xtl Biopharmaceuticals is $0.02.
-
What is the current market cap of Xtl Biopharmaceuticals?
The current market capitalization of Xtl Biopharmaceuticals is $12.6M.
-
Who are Xtl Biopharmaceuticals’s competitors?
Vicore Pharma Holding, Gilead Sciences, Ona Therapeutics, Genentech, and Pfizer Pakistan are some of the 20 competitors of Xtl Biopharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
